Clinical and Prognostic Significance of TSC2 and TSC1 Expressions in Rectal Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
TSC1 is a crucial component of the mTOR pathway, impacting cell growth, proliferation, and autophagy, while TSC2 is a tumor suppressor gene that regulates cell growth and is associated with the mTOR signaling pathway. In the present study, we analyzed TSC1 and TSC2 mRNA expression levels in rectal cancer, and evaluated clinicopathological and prognostic characteristics of TSC1 and TSC2. TSC1 and TSC2 mRNA expression was examined in various cancer types using The Cancer Genome Atlas (TCGA) data. The patients were split into two subgroups, each comprising 50% of the total, based on the TSC gene expression levels. This division was made to assess the clinical characteristics associated with the expression of TSC1 and TSC2 genes. Lower TSC1 expression was linked to venous invasion in rectal cancer patients, and there was also a related trend with lymphatic invasion, although it didn’t reach statistical significance. Lower TSC2 expression was observed in younger patients and had some associations with sex and M stage, but these correlations were not statistically significant. When it came to survival analysis, TSC1 expression did not significantly impact overall survival, while higher TSC2 expression was associated with a poorer prognosis in rectal cancer. TSC1 and TSC2 may have important role in rectal cancer and its molecular mechanisms and clinical characteristics should be studied further.
Abstract
TSC1 is a crucial component of the mTOR pathway, impacting cell growth, proliferation, and autophagy, while TSC2 is a tumor suppressor gene that regulates cell growth and is associated with the mTOR signaling pathway. In the present study, we analyzed TSC1 and TSC2 mRNA expression levels in rectal cancer, and evaluated clinicopathological and prognostic characteristics of TSC1 and TSC2. TSC1 and TSC2 mRNA expression was examined in various cancer types using The Cancer Genome Atlas (TCGA) data. The patients were split into two subgroups, each comprising 50% of the total, based on the TSC gene expression levels. This division was made to assess the clinical characteristics associated with the expression of TSC1 and TSC2 genes. Lower TSC1 expression was linked to venous invasion in rectal cancer patients, and there was also a related trend with lymphatic invasion, although it didn’t reach statistical significance. Lower TSC2 expression was observed in younger patients and had some associations with sex and M stage, but these correlations were not statistically significant. When it came to survival analysis, TSC1 expression did not significantly impact overall survival, while higher TSC2 expression was associated with a poorer prognosis in rectal cancer. TSC1 and TSC2 may have important role in rectal cancer and its molecular mechanisms and clinical characteristics should be studied further.
참고문헌 (22)
- Aboelela DA, "Potential diagnostic role of circulating MiRNAs in colorectal cancer", Int J Immunopathol Pharmacol, 37 (2023)
- Kim J, "Detection of Colorectal Adenocarcinoma and Grading Dysplasia on Histopathologic Slides Using Deep Learning", Am J Pathol, 193, pp.332~340 (2022)
- Grady WM, "Genomic and epigenetic instability in colorectal cancer pathogenesis", Gastroenterology, 135, pp.1079~1099 (2008)
- Khan K, "Colorectal cancer with liver metastases : neoadjuvant chemotherapy, surgical resection first or palliation alone?", World J Gastroenterol, 21, pp.12391~12406 (2014)
- Ma SC, "Novel strategies to reverse chemo-resistance in colorectal cancer", Cancer Med, 12, pp.11073~11096 (2023)
- González-Villaseñor CO, "A novel mutation in the TSC2 gene protects against colorectal cancer in the Mexican population", Gac Med Mex, 158, pp.283~288 (2022)
- Mallela K, "Role of TSC1 in physiology and diseases", Mol Cell Biochem, 476, pp.2269~2282 (2021)
- Lai M, "Tsc1 regulates tight junction independent of mTORC1", Proc Natl Acad Sci U S A, 27, pp.118~ (2021)
- Maiese K, "Moving to the Rhythm with Clock(Circadian)Genes, Autophagy, mTOR, and SIRT1 in Degenerative Disease and Cancer", Curr Neurovasc Res, 14, pp.299~304 (2017)
- D’Armiento J, "Mesenchymal Tumorigenesis Driven by TSC2 Haploinsufficiency Requires HMGA2 and Is Independent of mTOR Pathway Activation", Cancer Res, 15, pp.844~854 (2016)
- Kim J, "Analysis of the Cancer Genome Atlas Data to Determine the Prognostic Value of GABPB1L and TERT in Glioblastoma", Keimyung Med J, 40, pp.73~76 (2021)
- Kim J, "Clinical and Prognostic Values of DNMT3B Expression in Hepatocellular Carcinoma", Keimyung Med J, 41, pp.13~16 (2022)
- Specchio N, "Autism and Epilepsy in Patients With Tuberous Sclerosis Complex", Front Neurol, 11, pp.639~ (2020)
- Specchio N, "Familial Kidney Cancer : Implications of New Syndromes and Molecular In-sights", Eur Urol, 76, pp.754~764 (2019)
- Feng Y, "Programmed death-ligand 1 and mammalian target of rapamycin signaling pathway in locally advanced rectal cancer", Discov Oncol, 13, pp.10~ (2022)
- Johnson SM, "Novel expression patterns of PI3K", Akt, J Am Coll Surg, pp.2010, 210[DOI]
- Dowling RJ, "mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs", Science, 328, pp.1172~1176 (2010)
- Göktuna Sİ, "IKBKE inhibits TSC1 to activate the mTOR", S6K pathway for oncogenic transformation, 2018, pp.42, 268~278
- Lee SJ, "Genetic variations in STK11, PRKAA1, and TSC1 associated with prognosis for patients with colorectal cancer", Ann Surg Oncol, 21, pp.634~639 (2014)
- Simons CCJM, "Polymorphisms in the mTOR-PI3K-Akt pathway, energy balance-related exposures and colorectal cancer risk in the Netherlands Cohort Study", Bio Data Min, 15, pp.2~ (2022)
- Lee S, "Differential expression in normal-adenoma-carcinoma sequence suggests complex molecular carcinogenesis in colon", Oncol Rep, 16, pp.747~754 (2006)
- Zhu QY, "The role of TSC2 in breast cancer : a literature review", Front Oncol, 12, pp.1188371~ (2023)